Serve as the trusted and recognized industry voice at both national and state levels for prescription psychedelic medicine. We demonstrate the critical importance of government-sponsored research and public-private partnerships to build the infrastructure required for this innovative medical frontier.
Promote accurate, science-based information by educating policymakers, regulators, and stakeholders about the safety profiles and clinical efficacy of psychedelics and entactogens. We aim to replace stigma with data regarding the specific medical conditions these compounds are designed to treat.
Prioritize ethical standards in research and administration to ensure patient safety and well-being. We champion the adoption of FDA-approved prescription psychedelics provided by licensed healthcare providers in structured, supervised clinical settings.
Advance responsible legislative policies that drive innovation and increase funding for research. We advocate for a streamlined regulatory pathway that ensures insurance coverage and broad, equitable access to these life-saving therapies.
Foster collaboration among industry, academic researchers, healthcare professionals, policy makers and patients to advance understanding and integration of prescription psychedelic medicine into the healthcare system.
Co-Founder & Executive Director
Co-Founder & Sr. Advisor
Member of Congress (ret.)
Professor and Heersink Endowed Chair of Psychiatry | University of Alabama at Birmingham
Scientific Advisor
Ralph Metzner Distinguished Professor of Neurology, Psychiatry and Behavioral Sciences | University of California San Francisco
Scientific Advisor
Director of the UW Madison Transdisciplinary Center for Research in Psychoactive Substances | University of Wisconsin
Scientific Advisor
Senior Researcher | Sheppard Pratt
Scientific Advisor
President, Co-Founder | Heffter Research Institute
Scientific Advisor
Clinical Director, Cleveland Clinic Psychiatric Treatment Resistance Program | Cleveland Clinic
Scientific Advisor
Scientific Advisor
Assistant Professor of Psychiatry and Behavioral Sciences | John’s Hopkins School of Medicine
Scientific Advisor
Psychiatrist/Instructor | Massachusetts General Hospital/Harvard Medical School
APP is supported by a coalition of innovative pharmaceutical companies and organizations that share our commitment to the development of safe, effective, and FDA-approved prescription psychedelic medicines.
The Association for Prescription Psychedelics (APP) works to advance the development and accessibility of safe and effective prescription psychedelic medicines for patients. We serve as the trusted and recognized industry voice – at the national and state levels – on prescription psychedelic medicine and its integration into the health care system.
Our efforts help ensure that policymakers, regulators, and other key stakeholders are educated about the breadth of the industry and the diversity of classic psychedelics and their differences from entactogens/empathogens and dissociatives, as well as the different ways in which psychedelics may be administered and the potential medical conditions they treat.
Our advocacy efforts help advance responsible legislative and regulatory policies that drive innovation, increase funding for research, and enhance access and coverage for prescription psychedelic medicine.
America is facing an unprecedented mental health crisis: suicide rates are unacceptable, and the standard of care has not advanced in decades. With more than 60 clinical trials in the last 10 years showing substantial data, we must act now to provide new tools for patients who have run out of options.
APP is focused exclusively on the medical model. We advocate for FDA-approved prescription medicines administered by licensed professionals in healthcare settings, distinguishing our mission from broad decriminalization or legalization efforts.
We do not advocate for psychotherapy – our efforts are focused on advancing the development and accessibility of safe and effective prescription psychedelic medicines for patients. While treatment plans vary by compound and condition, our priority is ensuring that every intervention follows established regulatory guidance and proven medical standards of care.
We believe we will have strong support from both sides of the aisle. Both sides recognize the mental health crisis we are facing in this country, and we look forward to continuing to work with all members of Congress and the new administration on potentially bringing forward psychedelics as FDA-approved therapies.
